[1] Ganesan P, Kulik L M. Hepatocellular carcinoma: new developments[J]. Clin Liver Dis, 2023, 27(1): 85-102.
[2] Moris D, Martinino A, Schiltz S, et al. Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians[J]. CA Cancer J Clin, 2025, 75(6): 498-527.
[3] Mackowiak B, Fu Y, Maccioni L, et al. Alcohol-associated liver disease[J]. J Clin Invest, 2024, 134(3).
[4] Ma L, Chen S, Wang H, et al. Hepatitis B virus integration and hepatocarcinogenesis[J]. Liver Res, 2025, 9(3): 189-198.
[5] Rumgay H, Shield K, Charvat H, et al. Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study[J]. Lancet Oncol, 2021, 22(8): 1071-1080.
[6] Huang D Q, Mathurin P, Cortez-Pinto H, et al. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(1): 37-49.
[7] Liang Y J, Chiou Y W, Chiu A P, et al. Antiviral therapy reduces hepatocellular carcinoma through suppressing hepatitis B virus replication may improve ER stress, mitochondrial and metabolic dysfunctions and decrease p62 in hybridized mice with single HBV transgene and miR-122[J]. J Med Virol, 2023, 95(12): e29325.
[8] Zhou H, Ba J, Xiao C, et al. Alcohol activates ATF4/LPLA2-mediated BMP metabolism to enhance HBV-induced hepatocellular carcinogenesis[J]. J Hepatol, 2026, 84(2): 339-354.
[9] Yang L, Zou T, Chen Y, et al. Hepatitis B virus X protein mediated epigenetic alterations in the pathogenesis of hepatocellular carcinoma[J]. Hepatol Int, 2022, 16(4): 741-754.
[10] Sivasudhan E, Blake N, Lu Z, et al. Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma: a comprehensive review[J]. Cells, 2022, 11(4).
[11] Chan L K, Ho D W, Kam C S, et al. RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma[J]. J Hepatol, 2021, 74(2): 360-371.
[12] Loureiro D, Tout I, Narguet S, et al. Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis[J]. Hepatology, 2023, 77(4): 1348-1365.
[13] Aghara H, Chadha P, Zala D, et al. Stress mechanism involved in the progression of alcoholic liver disease and the therapeutic efficacy of nanoparticles[J]. Front Immunol, 2023, 14: 1205821.
[14] Chen X, Cubillos-Ruiz J R. Endoplasmic reticulum stress signals in the tumour and its microenvironment[J]. Nat Rev Cancer, 2021, 21(2): 71-88.
[15] Seo W, Gao Y, He Y, et al. ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles[J]. J Hepatol, 2019, 71(5): 1000-1011.
[16] Tang Y L, Zhu L, Tao Y, et al. Role of targeting TLR4 signaling axis in liver-related diseases[J]. Pathol Res Pract, 2023, 244: 154410.
[17] Casari M, Siegl D, Deppermann C, et al. Macrophages and platelets in liver fibrosis and hepatocellular carcinoma[J]. Front Immunol, 2023, 14: 1277808.
[18] Khanam A, Tang L, Kottilil S. Programmed death 1 expressing CD8+ CXCR5+ follicular T cells constitute effector rather than exhaustive phenotype in patients with chronic hepatitis B[J]. Hepatology, 2022, 75(3): 690-708.
[19] Heinz R, Waltenbaugh C. Ethanol consumption modifies dendritic cell antigen presentation in mice[J]. Alcohol Clin Exp Res, 2007, 31(10): 1759-1771.
[20] Wu Y, Hao X, Wei H, et al. Blockade of T-cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBV-related HCC in mice[J]. Hepatology, 2023, 77(3): 965-981.
[21] Yang Z, Liu Z, Liu W, et al. Steatotic liver disease and cancer: from pathogenesis to therapeutic targets[J]. eGastroenterology, 2025, 3(3): e100218.
[22] Peng B, Li H, Liu K, et al. Intrahepatic macrophage reprogramming associated with lipid metabolism in hepatitis B virus-related acute-on-chronic liver failure[J]. J Transl Med, 2023, 21(1): 419.
[23] Ajoolabady A, Aslkhodapasandhokmabad H, Zhou Y, et al. Epigenetic modification in alcohol-related liver diseases[J]. Med Res Rev, 2022, 42(4): 1463-1491.
[24] Ventura-Cots M, Argemi J, Jones P D, et al. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease[J]. Gut, 2022, 71(9): 1856-1866.
[25] You H, Wang X, Ma L, et al. Insights into the impact of hepatitis B virus on hepatic stellate cell activation[J]. Cell Commun Signal, 2023, 21(1): 70.
[26] Molenaar M R, Haaker M W, Vaandrager A B, et al. Lipidomic profiling of rat hepatic stellate cells during activation reveals a two-stage process accompanied by increased levels of lysosomal lipids[J]. J Biol Chem, 2023, 299(4): 103042.
[27] Cruise T M, Kotlo K, Malovic E, et al. Advances in DNA, histone, and RNA methylation mechanisms in the pathophysiology of alcohol use disorder[J]. Adv Drug Alcohol Res, 2023,3: 10871.
[28] Gan W, Kang Y, Wu Y, et al. Hepatitis B virus X protein induces p16 gene promoter methylation through upregulation of DNA methylation transferases DNMT1 and DNMT3A[J]. Adv Clin Exp Med, 2023, 32(5): 583-592. |
